Histologically low-grade, yet biologically high-grade, canine cutaneous mast cell tumours: A systematic review and meta-analysis of individual participant data.
medical oncology
neoplasm staging
neoplasms
surgical oncology
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
27
11
2019
revised:
30
01
2020
accepted:
20
02
2020
pubmed:
28
2
2020
medline:
25
8
2021
entrez:
28
2
2020
Statut:
ppublish
Résumé
Low-grade canine cutaneous mast cell tumour (cMCT) with metastasis at the time of treatment is uncommonly reported, with few studies focusing on this specific clinical entity. The specific objective of this study was to systematically review the veterinary literature and perform a meta-analysis summarizing the clinical presentation, treatments reported and clinical outcomes from dogs with histologically low-grade cMCT and metastasis present at initial treatment. A total of 980 studies were screened with eight publications providing data on 121 dogs ultimately included. The most common treatments were surgery with adjuvant chemotherapy in 83/121 (69%) dogs; combined surgery, radiation and chemotherapy in 17/121 (14%) dogs; chemotherapy alone in 12/121 (10%) dogs and surgery alone in 7/121 (6%) dogs. Dogs with distant metastasis (n = 22) experienced significantly shorter survival compared with those with regional lymph node (RLN) metastasis (n = 99; median 194 vs 637 days; P < .01). Two variables were significantly associated with increased risk of death: presence of distant (vs RLN) metastasis (hazard ratio = 2.60; P < .01) and not receiving surgery as a component of treatment (hazard ratio = 3.79; P < .01). Risk of bias was judged to be low in terms of selection and performance bias but high in terms of detection and exclusion bias. In conclusion, dogs with cMCT and RLN metastasis can be expected to live significantly longer than those with distant metastasis, and surgery appears to have a role in extending survival of metastatic low-grade cMCT.
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
580-589Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
London CA, Thamm DH. Ch.20: mast cell tumours. In: Withrow SJ, Vail DM, Page RL, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 5th ed. St. Louis, MO: Elsevier; 2013:335-380.
McNiel EA, Prink AL, O'Brien TD. Evaluation of risk and clinical outcome of mast cell tumours in pug dogs. Vet Comp Oncol. 2006;4(1):2-8.
Kiupel M, Webster JD, Miller RA, Kaneene JB. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours. J Vet Med Ser. 2005;52(6):280-286.
Gieger TL, Théon AP, Werner JA, McEntee MC, Rassnick KM, DeCock HE. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001). J Vet Intern Med. 2003;17(5):687-692.
Hillman LA, Garrett LD, de Lorimier LP, Charney SC, Borst LB, Fan TM. Biological behavior of oral and perioral mast cell tumors in dogs: 44 cases (1996-2006). J Am Vet Med Assoc. 2010;237(8):936-942.
Schwab TM, Popovitch C, DeBiasio J, Goldschmidt M. Clinical outcome for MCTs of canine pinnae treated with surgical excision (2004-2008). J Am Anim Hosp Assoc. 2014;50(3):187-191.
Murphy S, Sparkes AH, Blunden AS, Brearley MJ, Smith KC. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Vet Rec. 2006;158(9):287-291.
Krick EL, Billings AP, Shofer FS, Watanabe S, Sorenmo KU. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival. Vet Comp Oncol. 2009;7(2):130-138.
Horta RS, Lavalle GE, Monteiro LN, Souza MCC, Cassali GD, Araújo RB. Assessment of canine mast cell tumor mortality risk based on clinical, histologic, immunohistochemical, and molecular features. Vet Pathol. 2018;55(2):212-223.
Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol. 1984;21(5):469-474.
Murphy S, Sparkes AH, Brearley MJ, Smith KC, Blunden AS. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec. 2004;154(24):743-746.
Kiupel M, Webster JD, Bailey KL, et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol. 2011;48(1):147-155.
Elston LB, Sueiro FA, Cavalcanti JN, Metze K. Letter to the editor: the importance of the mitotic index as a prognostic factor for survival of canine cutaneous mast cell tumors: a validation study. Vet Pathol. 2009;46(2):362-364.
Romansik EM, Reilly CM, Kass PH, Moore PF, London CA. Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Vet Pathol. 2007;44(3):335-341.
Kiupel M, Camus M. Diagnosis and prognosis of canine cutaneous mast cell tumors. Vet Clin North Am Small Animal Pract. 2019;49(5):819-836.
Stefanello D, Buracco P, Sabattini S, et al. Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014). J Am Vet Med Assoc. 2015;246(7):765-769.
Turrel JM, Kitchell BE, Miller LM, Théon A. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs. J Am Vet Med Assoc. 1988;193(8):936-940.
Seguin B, Leibman NF, Bregazzi VS, et al. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). J Am Vet Med Assoc. 2001;218(7):1120-1123.
Weisse C, Shofer FS, Sorenmo K. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc. 2002;38(1):71-73.
Miller RL, Lelyveld SV, Warland J, Dobson JM, Foale RD. A retrospective review of treatment and response of high-risk mast cell tumours in dogs. Vet Comp Oncol. 2014;14(4):361-370.
Baginski H, Davis G, Bastian RP. The prognostic value of lymph node metastasis with grade 2 MCTs in dogs: 55 cases (2001-2010). J Am Anim Hosp Assoc. 2014;50(2):89-95.
Olsen JA, Thomson M, O'Connell K, Wyatt K. Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs. Vet Med Sci. 2018;4(3):237-251.
Lejeune A, Skorupski K, Frazier S, et al. Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012). Vet Comp Oncol. 2013;13(3):267-280.
Weishaar KM, Thamm DH, Worley DR, Kamstock DA. Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis. J Comp Pathol. 2014;151(4):329-338.
Schulman FY. The prognostic significance of microscopic lymph node metastasis of Patnaik grade I and II/Kiupel low-grade MCTs has not been demonstrated. Vet Comp Oncol. 2019;17(2):208.
Schulman FY. Is lymph node metastasis of canine grade 2 MCTs justification for adjuvant therapy? Vet Comp Oncol. 2015;13(2):151-151.
Ferrari R, Marconato L, Buracco P, et al. The impact of extirpation of non-palpable/normal-sized regional lymph nodes on staging of canine cutaneous mast cell tumours: a multicentric retrospective study. Vet Comp Oncol. 2018;16(4):505-510.
Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657-1665.
Ryan S, GH E, van Nimwegen SA, Kirpensteijn J. Ch.4: skin and subcutaneous tumors. In: Kudnig ST, Bernard S, eds. Veterinary Surgical Oncology. Ames, IA: JohnWiley & Sons; 2012:61-69.
van Nimwegen SA, Kirpensteijn J. Ch.82: specific disorder of the skin and subcutaneous tissues. In: Johston SA, Tobias KM, eds. Veterinary Surgery: Small Animal. Vol. 2. 2nd ed. Elsvier: St. Louis, MO; 2018:1535-1543.
Bae S, Milovancev M, Bartels C. Histologically low-grade, yet biologically high-grade, canine cutaneous mast cell tumours: a systematic review and meta-analysis of individual participant data. [dataset]. Figshare. https://doi.org/10.6084/m9.figshare.11273798.v1.
Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Persp. 2013;121(9):985-992.
Higgins JPT, Altman DG, Sterne JAC. Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, eds. Cochrane Handbook for Systematic Reviews of Interventions. V5.2.0 edn. Chichester, England: The Cochrane Collaboration; 2017. https://training.cochrane.org/handbook#how-to-cite.
Book AP, Fidel J, Wills T, Bryan J, Sellon R, Mattoon J. Correlation of ultrasound findings, liver and spleen cytology, and prognosis in the clinical staging of high metastatic risk canine mast cell tumors. Vet Radiol Ultrasoun. 2011;52(5):548-554.
Hughes JR, Szladovits B, Drees R. Abdominal CT evaluation of the liver and spleen for staging mast cell tumors in dogs yields nonspecific results. Vet Radiol Ultrasoun. 2019;60(3):306-315.
Marconato L, Polton G, Stefanello D, et al. Therapeutic impact of regional lymphadenectomy in canine stage II cutaneous mast cell tumours. Vet Comp Oncol. 2018;16(4):580-589.
Milovancev M, Townsend KL, Tuohy JL, et al. Long-term outcomes of dogs undergoing surgical resection of mast cell tumors and soft tissue sarcomas: a prospective 2-year-long study. Vet Surg. 2019;49:96-105.
Fox LE, Rosenthal RC, Twedt DC, Dubielzig RR, MacEwen EG, Grauer GF. Plasma histamine and gastrin concentrations in 17 dogs with mast cell tumors. J Vet Intern Med. 1990;4(5):242-246.
Moirano S, Lima S, Hume K, Brodsky E. Association of prognostic features and treatment on survival time of dogs with systemic mastocytosis: a retrospective analysis of 40 dogs. Vet Comp Oncol. 2017;16(1):E194-E201.
Pizzoni S, Sabattini S, Stefanello D, et al. Features and prognostic impact of distant metastases in 45 dogs with de novo stage IV cutaneous mast cell tumours: a prospective study. Vet Comp Oncol. 2017;16(1):28-36.
O'Keefe DA, Couto GC, Burke-Schwartz C, Jacobs RM. Systemic mastocytosis in 16 dogs. J Vet Intern Med. 1987;1(2):75-80.
Scarpa F, Sabattini S, Marconato L, Capitani O, Morini M, Bettini G. Use of histologic margin evaluation to predict recurrence of cutaneous malignant tumors in dogs and cats after surgical excision. J Am Vet Med Assoc. 2012;240(10):1181-1187.
Thamm D, Turek M, Vail D. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci. 2006;68(6):581-587.
Girolamo DN, Giuffrida MA, Winter AL, Meursinge RR. In veterinary trials reporting and communication regarding randomisation procedures is suboptimal. Vet Rec. 2017;181(8):195.
Sargeant JM, O'Connor A, Dohoo IR, et al. Methods and processes of developing the strengthening the reporting of observational studies in epidemiology − veterinary (STROBE-Vet) statement. Prev Vet Med. 2016;134:188-196.
Chaffin K, Thrall DE. Results of radiation therapy in 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis. Vet Radiol Ultrasoun. 2002;43(4):392-395.
Poirier VJ, Adams WM, Forrest LJ, Green EM, Dubielzig RR, Vail DM. Radiation therapy for incompletely excised grade II canine mast cell tumors. J Am Anim Hosp Assoc. 2006;42(6):430-434.